BioSpace News Archive

CYduct Diagnostics, Inc. is pleased to announce it has joined BioCT, Connecticut’s Biosciences Community.

The Analgesic Program, which commenced in July 2018 to discover and develop peptide-based therapeutics for moderate to severe pain and inflammation, and was successfully completed in March 2021.

Israeli biotechnology company, BioGenCell, founded by Dr. Yael Porat and Prof. Michael Belkin, and developer of unique technology for using stem cells from the patient’s own blood to treat microvascular diseases, has completed a $16 million seed round, led by Marius Nacht, Israel’s largest private biotech investor.

BIOQUAL, Inc., announced that Dave Newcomer will retire from his role as Chief Financial Officer effective June 3, 2022.

Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today reported financial results and key operational progress updates for the first quarter ending March 31, 2022.

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced financial results for the first quarter ended March 31, 2022 and provided business updates.

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the first quarter ended March 31, 2022, and provided a business update.

Quantum-Si Incorporated announced financial results for the first quarter ending March 31, 2022.

Precision BioLogic Inc. a leading developer of hemostasis diagnostic products, is pleased to announce the launch of its new CRYO check Chromogenic Factor IX assay in Canada, the European Union, Australia, and New Zealand.

BlueWind Medical, Ltd., developer of the innovative RENOVA iStim implantable tibial neuromodulation device under investigation for the treatment of urgency incontinence alone or in combination with urinary urgency and/or urinary frequency, announced the closing of a $64 million Series B funding round.